View in EDS

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.

Saved in:
Bibliographic Details
Title: Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.
Authors: Vianna P; Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Chakraborty R; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Hossain S; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Bhutani D; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Miller S; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Rossi A; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA., Cuddy SAM; Harvard Medical School, Boston, MA.; Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Falk RH; Harvard Medical School, Boston, MA.; Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA., Lentzsch S; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Laubach JP; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA., Bianchi G; Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.
Source: Blood [Blood] 2025 Oct 16; Vol. 146 (16), pp. 1929-1935.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40712156
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Vianna+P%22">Vianna P</searchLink>; Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Chakraborty+R%22">Chakraborty R</searchLink>; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Hossain+S%22">Hossain S</searchLink>; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Bhutani+D%22">Bhutani D</searchLink>; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Miller+S%22">Miller S</searchLink>; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Rossi+A%22">Rossi A</searchLink>; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Cuddy+SAM%22">Cuddy SAM</searchLink>; Harvard Medical School, Boston, MA.; Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Falk+RH%22">Falk RH</searchLink>; Harvard Medical School, Boston, MA.; Amyloidosis Program, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Lentzsch+S%22">Lentzsch S</searchLink>; Division of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Laubach+JP%22">Laubach JP</searchLink>; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Bianchi+G%22">Bianchi G</searchLink>; Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA.; Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA.; Harvard Medical School, Boston, MA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%227603509%22">Blood</searchLink> [Blood] 2025 Oct 16; Vol. 146 (16), pp. 1929-1935.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>7603509 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1528-0020 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200064971%22">00064971 </searchLink><i>NLM ISO Abbreviation: </i>Blood <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40712156
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1182/blood.2025028383
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1929
    Titles:
      – TitleFull: Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Vianna P
      – PersonEntity:
          Name:
            NameFull: Chakraborty R
      – PersonEntity:
          Name:
            NameFull: Hossain S
      – PersonEntity:
          Name:
            NameFull: Bhutani D
      – PersonEntity:
          Name:
            NameFull: Miller S
      – PersonEntity:
          Name:
            NameFull: Rossi A
      – PersonEntity:
          Name:
            NameFull: Cuddy SAM
      – PersonEntity:
          Name:
            NameFull: Falk RH
      – PersonEntity:
          Name:
            NameFull: Lentzsch S
      – PersonEntity:
          Name:
            NameFull: Laubach JP
      – PersonEntity:
          Name:
            NameFull: Bianchi G
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 16
              M: 10
              Text: 2025 Oct 16
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1528-0020
          Numbering:
            – Type: volume
              Value: 146
            – Type: issue
              Value: 16
          Titles:
            – TitleFull: Blood
              Type: main
ResultId 1